Tysabri Backlash: GSK’s Phase II Multiple Sclerosis Drug On Clinical Hold
This article was originally published in The Pink Sheet Daily
Executive Summary
GSK drug is a dual alpha-4 integrin antagonist, the same mechanism of action as Tysabri. Biogen Idec/Elan suspended Tysabri marketing based on a safety signal. GSK had expected to file an NDA for ’699 in 2008.
You may also be interested in...
Novartis's Phase III Program For MS Agent FTY720 Delayed By Safety Request From FDA
Firm previously had projected a mid-year start for Phase III studies of the oral multiple sclerosis treatment. Novartis says the revised timeframe will allow for an FDA-requested safety analysis relating to FTY720's use in renal transplantation.
Novartis's Phase III Program For MS Agent FTY720 Delayed By Safety Request From FDA
Firm previously had projected a mid-year start for Phase III studies of the oral multiple sclerosis treatment. Novartis says the revised timeframe will allow for an FDA-requested safety analysis relating to FTY720's use in renal transplantation.
Tysabri Could Return In Fall; Marketing Suspended By Biogen Idec And Elan
One fatal, confirmed case of progressive multifocal leukoencephalopathy and one suspected case prompt withdrawal of multiple sclerosis product; risk/benefit ratio needs to be reestablished, companies say. Return to market would not be unprecedented, but Tysabri’s withdrawal sharpens focus on FDA's drug safety oversight.